MYFORTIC 360 MG TABLET

What it is

MYFORTIC 360 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as mycophenolic acid, under the trade name “Myfortic”.

FDA gives its dosage form as tablet, delayed release and its route as oral.

The labeler, the company named on the label, is Novartis Pharmaceuticals Corporation.

FDA’s Established Pharmacologic Class for it is Antimetabolite Immunosuppressant.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00078-0386-66.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $448.03 for 30 tablets (30 × $14.9342 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-07-08. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 4, carried forward from the previous file.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-07-08. The file is new; the price is not.

NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $0.22157 per EA filed.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices

The NDC

• 00078-0386-66 · Novartis Pharmaceuticals Corporation · $14.9342 per EA · eff. 2026-07-08 filed carried forward

Other strengths, forms and brands

3 other products in the NADAC file share the FDA nonproprietary name mycophenolic acid with MYFORTIC 360 MG TABLET.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-08, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

Its NADAC price is $14.9342 per EA filed.

Of the 7 other products in FDA’s Antimetabolite Immunosuppressant class priced per EA, 1 has a higher middle NADAC price and 6 a lower one. The one in the middle is MYCOPHENOLATE 500 MG TABLET, at $0.26327 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-08, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS J7518, for 2026-10-01 to 2026-12-31, comes to $15.42 for 30 tablets, or $0.514 per EA once converted to NADAC’s unit for this product.

Medicare Part B pays for this oral drug at a pharmacy only in specific circumstances CMS sets for this code; most prescriptions are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.0514 per 180 MG.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.